Is Arena or VIVUS the Better Obesity Drug Stock?

Arena and VIVUS have had a tough year. Is it finally time to take the contrarian view and consider them worthy investments?

May 31, 2014 at 1:30PM

Investors had high hopes for Arena's (NASDAQ:ARNA) Belviq and VIVUS' (NASDAQ:VVUS) Qsymia when in 2012 they became the first new obesity drugs in 13 years to receive FDA approval. Yet by looking at how Arena and VIVUS have fared over the past year, it's clear that those hopes faded away quickly.

ARNA Chart

Source: Ycharts.

Considering those steep stock-price drops, it might be time to take the contrarian view and check if Arena and VIVUS are viable investments. Let's compare Arena to VIVUS in three key categories -- past sales, future sales growth, and fundamental valuations -- to see whether either stock is worth buying.

Past sales growth
Arena is partnered with Eisai (NASDAQOTH:ESALY) in marketing Belviq, and receives 31.5% of Eisai's worldwide sales of the drug. VIVUS doesn't have a marketing partner for Qsymia.

VIVUS launched Qsymia in September 2012, and Arena and Eisai launched Belviq in June 2013. Analysts had originally expected both drugs to generate annual peak sales over $1 billion.

Arena only reported $5.7 million in Belviq revenue in 2013 -- $5.3 million of which represented 31.5% of Eisai's net product sales ($16.8 million), along with $0.4 million from redemptions of free trial vouchers. Sales notably accelerated in the second half of the year: Arena's Belviq revenue rose 35% (excluding voucher redemptions) to $2.3 million between the third and fourth quarters of 2013. However, that surge is slowing -- leaving aside redemptions of vouchers, Arena's share of Belviq sales only increased 17% to $2.7 million in first quarter 2014.

VIVUS reported $23.7 million in Qsymia sales in 2013. Sales rose 20% sequentially in the fourth quarter to $7.7 million. But like Belviq, Qsymia's growth ramp began flattening out, as sequential sales growth was 18% in the first quarter, to $9.1 million.

That trend raises a troubling question: will demand for both drugs peak earlier than anticipated?

Future sales growth
Arena hopes that increased sales and marketing efforts with Eisai will pay off. On May 9, Arena announced that Eisai would boost its Belviq sales force by 50%, to approximately 600 sales representatives, and launch a television advertising campaign. Eisai had previously doubled its sales force from 200 to 400 representatives last October.

Arena has also been working with insurers and pharmacy benefits managers, or PBMs, to increase coverage. In February, Arena and Eisai signed a deal with CVS Caremark -- the second-largest PBM in the United States -- to help its drug reach more than half of Americans with insurance.

VIVUS secured a similar deal with Express Scripts, the nation's largest PBM, in late 2012. VIVUS also released a fitness app for smartphones, which provides information about Qsymia, last March.

In addition, health insurer Aetna has been evaluating both Belviq and Qsymia in a pilot weight-loss program, which could lead to better insurance coverage and availability for both drugs.

Fundamentals and financials
Comparing the fundamentals between Arena and VIVUS can be tricky for two reasons: both companies are currently unprofitable, rendering P/E and PEG ratios moot, and year-over-year sales growth isn't meaningful due to the recent commercial launches of Belviq and Qsymia.

Therefore, let's simply compare the two companies' price-to-sales, price-to-book, and cash/debt positions instead.

 

Price-to-sales

Price-to-book

Cash and equivalents

(mrq)

Total debt

(mrq)

Operating cash flow (ttm)

Arena

16

11

$257 million

$72 million

$72 million

VIVUS

5

4

$316 million

$217 million

($98 million)

Source: Yahoo Finance, May 29.

VIVUS appears to be the "cheaper" stock based on its price-to-sales and price-to-book ratios, but it's cheaper for a reason -- the company has a much higher debt-to-equity ratio than Arena and a negative operating cash flow.

Arena clearly has the upper hand financially, thanks to Eisai handling the heavy lifting in marketing and commercialization of Belviq. Although VIVUS lacks a major partner for Qsymia, its erectile dysfunction drug Stendra could help it bounce back financially. VIVUS has already secured three major licensing deals for Stendra with Menarini, Auxilium, and Sanofi to market the drug worldwide, which will boost VIVUS' revenue with up-front payments, royalties, and milestone payments.

The Foolish takeaway
Both Arena and VIVUS are risky investments, but Arena appears the stronger of the two. Arena's backing from Eisai could help it marginalize VIVUS and extend its drug's reach to more patients. VIVUS has made some smart moves by signing licensing deals for Stendra to boost revenue, but it's unclear if Stendra will eventually outweigh Qsymia's importance to the company's top line.

Still, I'm not convinced that either stock will do well moving forward, unless Belviq and Qsymia sales can show some stronger growth. Otherwise, sales of both drugs could plateau at pretty low numbers and cause both stocks to fall even further.

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

 

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark and Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers